Ensartinib clinical trials
Also written X-396.
How each study uses ensartinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ensartinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 18 Dec 2024 · ENSACOVE · NDA 218171 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
33 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2016 | 1 |
| 2017 | 4 |
| 2018 | 6 |
| 2019 | 3 |
| 2021 | 2 |
| 2022 | 6 |
| 2024 | 2 |
| 2025 | 6 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 21
Betta Pharmaceuticals Co., Ltd. (9) · National Cancer Institute (NCI) (3) · Xcovery Holdings, Inc. (3) · Sun Yat-sen University (2) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Peking University Cancer Hospital & Institute (2) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1)
Often tested with
Tested in the same studies.
Crizotinib (3) · Larotrectinib (2) · Erdafitinib (1) · Ivosidenib (1) · Olaparib (1) · Palbociclib (1) · LY3023414 (1) · Selpercatinib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 5
Studies that test ensartinib.
- Dec 2026Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung CancerPhase 2 · Nanjing First Hospital, Nanjing Medical University
- Jan 2027Treating Patients With Melanoma and ALK Alterations With EnsartinibPhase 2 · Memorial Sloan Kettering Cancer Center
- Feb 2027Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerPhase 2 · Hebei Medical University Fourth Hospital
- Sep 2027Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerPhase 1 · M.D. Anderson Cancer Center
- Nov 2027Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses ensartinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 33
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Ensartinib
- Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2Tang-Du HospitalNCT07354061Written as Ensartinib + Chemotherapy
- Study of MCLA-129 in Combination With Ensartinib in Patients With Advanced Solid Tumors.RecruitingPhase 1/2Betta Pharmaceuticals Co., Ltd.NCT07448116Written as Ensartinib
- Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLCNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07235306Written as Ensartinib 225mg
- Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma :A Multicenter, Real-World Clinical StudyNot yet recruitingPhase 4Fujian Medical University Union HospitalNCT06785584Written as Ensartinib
- Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung CancerNot yet recruitingPhase 2West China HospitalNCT06779539Written as Ensartinib
- Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRDNot yet recruitingPhase 2Peking University Cancer Hospital & InstituteNCT06780839Written as Ensartinib
- The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk FactorsNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06772610Written as Ensartinib group
- Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung CancerNot yet recruitingPhase 2Nanjing First Hospital, Nanjing Medical UniversityNCT06762327Written as Ensartinib
- Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung CancerRecruitingPhase 3Betta Pharmaceuticals Co., Ltd.NCT05341583Written as Ensartinib
- A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy VolunteersNot yet recruitingPhase 1Betta Pharmaceuticals Co., Ltd.NCT06492525Written as Ensartinib
- Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung CancerRecruitingPhase 2Hebei Medical University Fourth HospitalNCT05241028Written as Ensartinib
- A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung CancerNot yet recruitingPhase 2Sichuan UniversityNCT05186506Written as Ensatinib
- Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03155620Written as Ensartinib
- Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingPhase 2National Cancer Institute (NCI)NCT03213652Written as Ensartinib
- Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung CancerActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT04837716Written as Ensartinib
- Treating Patients With Melanoma and ALK Alterations With EnsartinibActive, not recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT03420508Written as Ensartinib
- Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 MutationActive, not recruitingPhase 2Sun Yat-sen UniversityNCT05491811Written as Ensartinib
- Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerCompletedPhase 1/2Xcovery Holdings, Inc.NCT01625234Written as Phase I: X-396 (ensartinib)
- Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung CancerTerminatedPhase 2National Cancer Institute (NCI)NCT03737994Written as Ensartinib
See all 33 studies that test ensartinib →
Given beside what is tested · 1 — ensartinib is usual care or a partner of the new treatment
Codes
What other systems call ensartinib · ClinicalTrials.gg INT001018
- MeSH (NLM) C000629294ensartinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) SMA5ZS5B22ENSARTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27896019ensartinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102754EnsartinibOne source FDA
- DrugBank DB14860One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629294 | ensartinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | SMA5ZS5B22 | ENSARTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27896019 | ensartinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102754 | Ensartinib | One source FDA |
| DrugBank | DB14860 | — | One source Wikidata |
Also registered as ensartinib hydrochloride (UNII C2FR6VT1BQ).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.